Evaluation of Therapeutic Effect of Low Dose Enoxaparin in Treatment of Psoriasis: Pilot Study | ||
| Al-Azhar International Medical Journal | ||
| Volume 2025, Issue 2, February 2025, Pages 195-201 PDF (511.66 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/aimj.2025.446439 | ||
| Authors | ||
| Amr Mohamed Zaky; Mohammad Elesawy Mohammad; Mohamed Mohamed Ahmed Mohamed Mostafa* | ||
| Dermatology, Venereology and Andrology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt | ||
| Abstract | ||
| Background: Psoriasis is an inflammatory skin condition that manifests as red, plaque-like lesions that are often covered with silvery-white scales. It is a chronic and recurrent immune-mediated skin disease. Aim and objectives: To assess the safety and effectiveness of treating plaque psoriasis with low doses of enoxaparin. Patients and methods: This study was conducted on 30 patients with plaque psoriasis(43.3%) males and(56.7%) females with a mean age of (37.7±13) years, ranging between(18-59) years, the patients had a mean disease duration (5.1±3.6) years, ranged between (1-16) years. Each patient was treated by 5mg enoxaparin(Clexane) as a subcutaneous injection once a week for 12 weeks. Results: There was statistically significant improvement in clinical response as 6 patients(20%) showed significant change, 12 patients(40%) showed moderate change, 8 patients (26.7%) showed no significant change, and finally, 4 patients(13.3%) were worsened. Conclusion: The excellent side-effect profile of low-dose enoxaparin makes it a promising new therapeutic choice for psoriasis. Concerning efficacy, additional large-scale trials are needed to ascertain the optimal dose and length of treatment, the subgroup of psoriasis to be treated, and to compare enoxaparin to conventional psoriasis remedies. | ||
| Keywords | ||
| Enoxaparin; Therapeutic effect; Psoriasis | ||
|
Statistics Article View: 53 PDF Download: 51 |
||
